Myriad Genetic Laboratories, Inc.
GPTKB entity
Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquisition |
Cynvenio Biosystems
SOPHi A GENETICS |
| gptkbp:awards |
Best Places to Work
Innovative Company Award Top 100 Healthcare Companies |
| gptkbp:business_model |
insurance partnerships
direct-to-consumer testing B2 B and B2 C |
| gptkbp:ceo |
Randy Scott
|
| gptkbp:clinical_lab |
CLIA certified
FDA registered CAP accredited |
| gptkbp:clinical_trial |
ongoing
|
| gptkbp:community_involvement |
patient advocacy
genetic counseling breast cancer awareness |
| gptkbp:conducts_research_on |
Dr. Jerry L. Spivak
|
| gptkbp:customer_base |
hospitals
physicians patients |
| gptkbp:employees |
approximately 1,000
|
| gptkbp:founded |
gptkb:1991
|
| gptkbp:founder |
gptkb:Mark_Skolnick
|
| gptkbp:global_presence |
international partnerships
operates in multiple countries |
| gptkbp:headcount_growth |
expanded internationally
increased since IPO |
| gptkbp:headquarters |
gptkb:Salt_Lake_City,_Utah
|
| https://www.w3.org/2000/01/rdf-schema#label |
Myriad Genetic Laboratories, Inc.
|
| gptkbp:industry |
genetic testing
|
| gptkbp:invention |
genetic testing technologies
over 500 patents biomarker discoveries |
| gptkbp:market_cap |
approximately $1 billion
|
| gptkbp:notable_products |
BRACAnalysis
my Risk |
| gptkbp:partnership |
gptkb:Mayo_Clinic
gptkb:Duke_University gptkb:Johns_Hopkins_University gptkb:University_of_Utah gptkb:Cleveland_Clinic |
| gptkbp:philanthropy |
scholarships for students
support for cancer research donations to health organizations |
| gptkbp:publicly_traded |
gptkb:NASDAQ
|
| gptkbp:regulatory_compliance |
gptkb:CLIA
gptkb:FDA CAP |
| gptkbp:research_focus |
pharmacogenomics
cancer genetics hereditary cancer |
| gptkbp:services |
molecular diagnostics
|
| gptkbp:stock_symbol |
gptkb:MYGN
|
| gptkbp:website |
myriad.com
|